Starpharma (ASX:SPL) says SPL7013, the antiviral agent in VIRALEZE nasal spray, achieved 95 per cent and 99.7 per cent reduction in viral infectivity against two significant types of influenza virus, A and B, respectively, in virucidal assays. …
Starpharma says SPL7013 in VIRALEZE virucidal against influenza A and B
May 19, 2022 Australian Biotech
Latest Video
New Stories
-
An institution dominated by very clever people, but where is the wisdom?
August 14, 2026 - - Latest News -
A plain language version of these dreadful and useless documents
August 14, 2026 - - Latest News -
CUREator+ backs six Australian startups with $13.5 million to advance new health technologies
August 13, 2026 - - Australian Biotech -
Medicines Australia appoints former AbbVie executive to key leadership role
August 13, 2026 - - Latest News -
VVMF and Optosleep partner to advance Australian gene therapy for sleep apnoea
August 13, 2026 - - Latest News -
Survey exposes deep gaps in neurological care across Australia
August 13, 2026 - - Latest News -
Australia 'is not an island' on pricing and we cannot be so arrogant to expect free product
August 13, 2026 - - Latest News